Entera Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 37
- Market Cap
- $62.4M
- Website
- http://www.enterabio.com
Clinical Trials
6
Active:1
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
3 (50.0%)Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Phase 1
Active, not recruiting
- Conditions
- HypoparathyroidismOsteoporosisFractures, BoneOther Disease
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT05965167
- Locations
- 🇮🇱
Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT04003467
- Locations
- 🇮🇱
Hadassah Medical Center, Mt. Scopus Hospital, Jerusalem, Israel
🇮🇱Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
🇮🇱Sheba Medical Center, Ramat-Gan, Israel
Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism
Phase 2
Completed
- Conditions
- Hypoparathyroidism
- Interventions
- Drug: EB612 (EBP05)Drug: NATPARA/NATPAR
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03516773
- Locations
- 🇮🇱
Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Safety and Bioavailability
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02571140
A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02202603
- Locations
- 🇮🇱
HMO Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
- Prev
- 1
- 2
- Next
News
No news found